![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to advance the company's platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease.
Lead Product(s): tRNA Medicine
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Flagship Pioneering
Deal Size: $109.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 09, 2023